ライフサイエンスコーパス: low-risk

1 utcomes), by risk classification (low or not low risk).

2 reatography (intermediate risk), or no test (low risk).

3 8 with non-null mutations were classified as low risk.

4 hout alcohol were perceived as situations of low risk.

5 increase in CVD events compared to those at low risk.

6 ort studies, 2825 (30.6%) were classified as low risk.

7 ocated 0-Is or 0-IIa granular lesions have a low risk.

8 set showed similar rates of CNS disease for low-risk (0.8%; CI, 0.0% to 1.6%), intermediate-risk (3.

9 osts were $9506 for practices categorized as low risk, $13683 for high medical risk only, $8214 for h

10 to high-risk (26%), standard-risk (29%), and low-risk (45%) groups, with different lengths of overall

11 es were delineated, with 5-year OS of 91% in low-risk, 66% in intermediate-risk (HR, 3.2; 95% CI, 1.9

12 for the MIPSS70 model; 5-year OS was 95% in low-risk, 70% in intermediate-risk, and 29% in high-risk

13 follow guidelines to survey individuals with low-risk adenomas (LRAs; 1-2 small tubular adenomas, < 1

14 = 1016), high-risk adenomas (HRA, n = 817), low-risk adenomas (n = 1418), and no adenomas (n = 3198)

15 the admissions, more common in survivors and low-risk admissions than in nonsurvivors and high-risk a

16 However, some patients are already at low risk after baseline colonoscopy and the value of sur

17 ears or immunocompromised [HIV-infected]) or low risk (aged 3 years or older and immunocompetent [HIV

18 dose naltrexone may represent a low-cost and low-risk alternative or adjunct in the treatment of HHD.

19 fied fewer patients with renal impairment as low risk and more as high risk, but with lower specifici

20 d 50 to 59 years, 88% (211 of 240) with very-low-risk and 68% (351 of 518) with low-risk disease chos

21 ian-level estimated rates of observation for low-risk and high-risk disease was assessed.

22 More important, the use of observation for low-risk and high-risk patients with prostate cancer is

23 els <133.3 pmol/l and >211.3 pmol/l detected low-risk and high-risk patients, respectively.

24 gist-level rates of observation for men with low-risk and high-risk prostate cancer.

25 identified two groups of patients with IPF (low-risk and high-risk), with significant differences in

26 and CML after RAI treatment was seen even in low-risk and intermediate-risk WDTC tumors.

27 ality, identifying patients at both high and low risk, and better correlated with follow-up renal fun

28 en missing physiologic data, admission type, low risk, and survival.

29 High-risk (HR), low-risk, and indeterminate-risk kSORT scores were obser

30 38%) of 65 patients were classified as being low-risk, and the probability of being non-dysplastic wa

31 ncreased risk for coprevalent disease versus low-risk asymptomatic contacts (14 [6%] of 224 vs 27 [2%

32 ne risk of malignancy and define a subset of low-risk BD-IPMNs.

33 young adulthood, whereas disparities between low-risk blacks and whites were related to differences i

34 ng/L identifies patients at presentation as low risk, but the optimal threshold is uncertain.

35 o were similarly categorised as high risk or low risk by the two risk scores.

36 reported and almost complete uptake for very-low-risk cancer.

37 These findings are timely for men with low-risk cancers who are being encouraged to consider ac

38 ) showed far greater suppression of TEs than low-risk cases.

39 162 (35%) of 468 of patients fell into the low-risk category and the probability of being a true no

40 The majority of readmissions were because of low-risk chest pain that did not require any interventio

41 ed on the basis of high-, intermediate-, and low-risk children.

42 At 1 year, the low risk class (RD-OGI Scores 0-2) had a 3% detachment r

43 Patients are excluded from "low-risk" classification and assigned "high-risk" status

44 that patients satisfy 8 criteria to achieve "low-risk" classification.

45 ermined: a high-risk, a moderate-risk, and a low-risk cluster (88.97%, 1.49%, 9.54% in 2009 and 82.42

46 tly higher in high-risk cluster than that in low-risk cluster.

47 her Gardnerella abundances replicated in the low-risk cohort, but not in the high-risk cohort.

48 ded to include patients at intermediate- and low-risk cohorts.

49 o (1.58 million), NS-colo (1.22 million), or low-risk comparator procedures (joint injection, aspirat

50 s pulmonary events were no higher than after low-risk comparator procedures.

51 ia (n = 8; excluded from survival analysis); low risk/completely necrotic (n = 7; zero relapses), int

52 ion of nontransplanted CKD patients and with low-risk control pregnancies, observed in Italy the new

53 ), 610 live-born singletons in CKD, and 1418 low-risk controls recruited in 2 large Italian Units in

54 etter power to discriminate high-risk versus low-risk coronary lesions than [(18)F]FDG.

55 EpxDialysis is a low-risk, cost-effective, intervention for increasing he

56 Most patients meeting very low-risk criteria can be safely managed by nephrectomy a

57 Prospective studies of women with "low-risk" DCIS treated with BCS alone have successfully

58 5% CI, 2.8 to 25.6) but not among those with low-risk disease (absolute difference, 0.7 percentage po

59 with very-low-risk and 68% (351 of 518) with low-risk disease chose active surveillance in 2014.

60 the estimated probability of observation for low-risk disease varied impressively (mean, 27.8%; range

61 ts, including 54 with high-risk and 133 with low-risk disease, have been treated.

62 oderate-risk drinkers, and most (90.2%) were low-risk drinkers.

63 In this low-risk elderly cohort, 46% of patients with a nonbacte

64 atric vaccination would reduce the number of low-risk elderly influenza cases to a greater extent tha

65 eness threshold of pound15 000 per QALY, the low-risk elderly seasonal vaccination programme will cea

66 greater extent than would vaccination of the low-risk elderly themselves if the elderly uptake is ach

67 substantial uncertainty exists as to whether low-risk elderly vaccination remains cost-effective, dri

68 , a strategy based on eliminating testing in low-risk farms resulted in a 40% reduction in sampling e

69 management and oral antibiotics were safe in low-risk FN with no infection-related mortality observed

70 ly benign clinical course, associated with a low risk for advanced heart failure symptoms, other dise

71 factors (CVRFs) is traditionally considered low risk for atherosclerosis; however, individuals witho

72 s among exceptional responders to NCT with a low risk for axillary metastases when breast pCR is docu

73 Twelve studies had low risk for bias, two had questionable risk, and 18 had

74 bolysis should be considered for patients at low risk for bleeding who have limb-threatening thrombos

75 that identifies patients with SIRS/sepsis at low risk for death and organ dysfunction.

76 ty of reporting (79 [28%] of 282), perceived low risk for injury (56 [20%] of 282), noncontaminated n

77 We find a potential Zika-related, low risk for microcephaly per pregnancy, but with signif

78 atory response syndrome (SIRS) and sepsis at low risk for organ dysfunction and death is a major clin

79 men: one predominantly Caucasian (n = 39) at low risk for PTB, the second predominantly African Ameri

80 e to identify patients with GNB infection at low risk for resistance to piperacillin-tazobactam (PT),

81 tion models to identify survivors at high or low risk for subsequent CNS tumors and validated these m

82 ify survivors of childhood cancer at high or low risk for subsequent CNS tumors on the basis of genet

83 ing of a structurally normal heart carries a low risk for sudden cardiac death; accordingly, there is

84 ied 17% of patients with renal impairment as low risk for the primary outcome (negative predictive va

85 on to be distinguished from HRLs that are at low risk for upgrade to cancer at surgery and thus could

86 ning model was developed to identify HRLs at low risk for upgrade to cancer.

87 if those categorized with the model to be at low risk for upgrade were surveilled and the remainder w

88 tisol levels in human subjects with high and low risks for obstructive sleep apnea (OSA).

89 cm for more than 5 years might be considered low-risk for progression to malignancy.

90 erm line (GL) were classified as oncogenetic low risk (gLoR; n = 111), whereas those with N/F GL and

91 ear RFS of 17.9% compared with 98.6% for the low risk group (P < 0.0001).

92 t the study population involved a relatively low risk group in a previously well-screened and treated

93 In a three-risk group model, the low-risk group (46% of all patients analyzed), the inter

94 CI, 0.52-0.78, respectively), but not in the low-risk group (risk ratio, 1.278; 95% CI, 0.888-1.839).

95 a trend that indicates that patients in the low-risk group could be at greater risk of suffering har

96 A hypothesized clinical low-risk group did not have a low risk of IBTR without R

97 tantially higher PARs were obtained when the low-risk group was compared with the US population.

98 17115 men with very-low-risk (subset of the low-risk group) (clinical stage, T1c; Gleason score, </=

99 es), low-risk (including all men in the very-low-risk group) (T1-T2; Gleason score, </=6; and PSA, <1

100 (intermediate-risk group, n=36), and 84.4% (low-risk group, n=202), and it provided greater net clin

101 Compared with the patients in the low-risk group, those in the medium- and high-risk group

102 ratio in cardiovascular risk assessment in a low-risk group.

103 d with the high-risk group compared with the low-risk group.

104 oss all willingness-to-pay thresholds in the low-risk group.

105 ce in median survival time between high- and low-risk groups (13.8 vs 10.7 years, respectively; P < .

106 sfully separated patients into high-risk and low-risk groups of disease progression.

107 lative incidences at age 50 years among CCSS low-risk groups were < 5%, compared with approximately 2

108 s in the ENTHUSE 33 trial into high-risk and low-risk groups with significantly different overall sur

109 tify patients into high-, intermediate-, and low-risk groups.

110 e (z score, -0.52 [95% CI, -0.71 to -0.33]), low risk had the next best cost score (z score, -0.18 [9

111 gh risk (hazard ratio, 2.830; P </= .001) or low risk (hazard ratio, 0.323; P </= .001) of experienci

112 arly all nonreproducible positive results in low-risk HCWs.

113 We conducted a cross-sectional study in low-risk health care workers (HCWs) at a single U.S. cen

114 n-specialists rapidly identify and de-label "low-risk" hospitalized patients with a label of PenA the

115 he prevalence of any high-risk HPV types and low-risk HPV types (mutually exclusive of high-risk HPV)

116 sk HPV16 and HPV18 E7 expression, but not by low-risk HPV6 and HPV11 E7 expression.

117 protecting against human papillomavirus and low-risk human papillomavirus.

118 sive days were considered to be suitable for low-risk immediate reverse triage.

119 hough whether this was due to study drugs or low risk in the population is uncertain.

120 The misclassification of these patients as "low risk," in combination with the low sensitivity of qu

121 ancer length in </=4 positive biopsy cores), low-risk (including all men in the very-low-risk group)

122 sk and BP individuals compared with healthy, low-risk individuals.

123 rst-degree relative with BP, and 53 healthy, low-risk individuals.

124 In a secondary analysis, low-risk infants received fewer examinations rather than

125 gh risk), examinations were indicated, while low-risk infants received no examinations.

126 However, if low-risk infants were examined at 37 weeks' postmenstrua

127 and were compared with 174 high-risk and 122 low-risk infants without ASD.

128 infants at high familial risk of ASD and 42 low-risk infants, we show that hyperexpansion of the cor

129 d on the pro-arrhythmia risk classification (Low risk, Intermediate risk, or High risk) established r

130 Low-risk intravenous chemotherapy agents had overuse tha

131 Men with low-risk, localised prostate cancer (Gleason pattern 3)

132 c therapy is a safe, effective treatment for low-risk, localised prostate cancer.

133 re classified as high-risk (LOH-positive) or low-risk (LOH-negative) patients based on their LOH prof

134 rnea (protein; P = 0.04) of HR compared with low-risk (LR) grafted hosts.

135 M for the identification of patients at very low risk (<5%) of having varices needing treatment (VNT)

136 The effect of RT in the presumed low-risk luminal A-like tumors was excellent.

137 (MBGrp3-HR [n=65] and MBGrp4-HR [n=85]) and low-risk (MBGrp3-LR [n=50] and MBGrp4-LR [n=73]) subgrou

138 enriched in high-risk MDS (in comparison to low-risk MDS), TP53, GATA2, KRAS, RUNX1, STAG2, ASXL1, Z

139 of disease stages encompassing preleukemia, low-risk MDS, high-risk MDS, and secondary AML.

140 The 2.5-year risks of tuberculosis in the low-risk, medium-risk, and high-risk groups were, respec

141 The 10-year risks of tuberculosis in the low-risk, medium-risk, and high-risk groups were, respec

142 ul observation are options for patients with low-risk micrometastatic disease, with due consideration

143 sisted 360-degree trabeculotomy is a useful, low-risk, modestly successful initial surgical treatment

144 The rate in low-risk MSM (16; 95% CrI, 4-38) was similar to that in

145 ant ovulating (n = 20) and high- (n = 9) and low-risk (n = 16) pregnant women to probes of varying si

146 ficiaries, 547 practices were categorized as low risk (neither high social nor high medical risk) (me

147 020 patients with atrial fibrillation with 1 low-risk, nonsex- related stroke risk factor.

148 in patients with atrial fibrillation with 1 low-risk, nonsex-related stroke risk factor.

149 ex > 50%, cold ischemia time > 24 hours) and low-risk (not having any risk factors, comprising approx

150 In low-risk (NUTrition Risk in the Critically Ill, < 5) and

151 lly lower mortality (odds ratios high versus low risk of 5-8 [ADHERE] and 11-18 [GWTG] across time po

152 l populations will limit exposure and have a low risk of adverse effects.

153 V-infected patients who are healthy and have low risk of AIDS-related outcomes should be included abs

154 d remained BE free at 1 year after RFA had a low risk of BE recurrence.

155 Seven trials (3 with low risk of bias) enrolled patients with mild to moderat

156 nce generation was judged to be adequate (at low risk of bias) in 32% ( n = 173) of trials, and basel

157 Four trials (1 with low risk of bias) included patients with predicted sever

158 tay in 4 of 7 studies (including 2 of 3 with low risk of bias).

159 Six studies were assessed as being at low risk of bias, and one was assessed as being at uncle

160 Three were at low risk of bias.

161 eared in randomized controlled trials with a low risk of bias.

162 ntal studies and 5 observational studies had low risk of bias.

163 uracy-2, all included studies were medium to low risk of bias.

164 er transplant recipients, including those at low risk of bleeding or high risk of thromboembolic comp

165 o 5 mm from the heart were associated with a low risk of cardiac complications.

166 three groups: high risk, moderate risk, and low risk of cardiac events, according to cardiovascular

167 se of expensive antiemetics in patients with low risk of chemotherapy-induced nausea and vomiting.

168 tion to posttransplantation, however, showed low risk of CMV replication (P < 0.001).

169 rally not cost-effective among patients with low risk of CNV, including those with no or few risk fac

170 ptimal cut-off scores to identify persons at low risk of complications were as follows: CP <5; MELD <

171 g clinical outcomes and to identify those at low risk of complications.

172 risk score, of whom 139 (83.2%) were also at low risk of complications.

173 In addition to a low risk of death, patients below this threshold had sho

174 These vaccine candidates should have a low risk of deattenuation because of the many changes in

175 In our model, ETV6-RUNX1 conferred a low risk of developing pB-ALL after exposure to common p

176 In this large population at low risk of diabetes, HBV and HCV infections were associ

177 undreds of organs per year, despite the very low risk of disease transmission.

178 this augmentation can be accomplished with a low risk of exacerbation of psychosis and adverse effect

179 he wider reef network, (2) have a relatively low risk of exposure to disturbances so that they are li

180 sociated with high BMD, high SM, low BR, and low risk of fractures [HR (95% CI) for osteoporotic frac

181 g on release by identifying those who are at low risk of future violent offending, and those at high

182 merism without toxic conditioning and with a low risk of graft versus host disease is a visionary but

183 admission, and identification of patients at low risk of harm, who are therefore suitable for outpati

184 In view of the low risk of HBV reactivation in anti-HBc alone patients

185 A score of <3 is associated with a low risk of HD and HCC 1 and 3 years after HCV diagnosis

186 6% had normal diastolic function and were at low risk of HF hospitalization or death (1%/y over a mea

187 patients with IBD incorrectly classified as low risk of IBD decreased from 16% to 9%.

188 patients without IBD correctly classified as low risk of IBD increased from 33% to 91%.

189 sized clinical low-risk group did not have a low risk of IBTR without RT, and RT reduced the rate of

190 lementation on birth outcomes among women at low risk of ID and the potential mechanisms for adverse

191 us to divest resources away from patients at low risk of malignancy.

192 n-malarial, low-breastfeeding setting with a low risk of mother-to-child transmission of HIV is uncle

193 non-malarial, low-breastfeeding areas with a low risk of mother-to-child transmission of HIV.

194 The V3-specific IgG binding that predicted low risk of mother-to-child-transmission (MTCT) was depe

195 tion of less than 5 ng/L identified those at low risk of myocardial infarction or cardiac death withi

196 an LVEF >/=40% at increased risk of SCD and low risk of nonsudden death who may benefit from implant

197 Findings were confirmed in subjects with a low risk of preclinical Alzheimer disease indexed by the

198 markers to identify a group of patients with low risk of progression suitable for non-endoscopic foll

199 be used to determine a group of patients at low risk of progression, for whom endoscopy could be avo

200 Lactobacillus crispatus was associated with low risk of PTB in both cohorts, while Lactobacillus ine

201 gLoR classifier, and MRD <10(-4) had a very low risk of relapse, with a 5-year CIR of only 2%.

202 es a significant subgroup of patients with a low risk of relapse.

203 high relaxivity (r 1 = 14.06 mM(-1) s(-1) ), low risk of release of Gd ions, and NIR-triggered drug r

204 ctive in most cases and is associated with a low risk of thromboembolism.

205 cellent in vitro and in vivo activities, and low risk of toxicity profile except for the inhibition o

206 cal practice by identifying those who are at low risk of violent offending.

207 risk for disease transmission (IRD) accept a low risk of window period infection, yet those who decli

208 ed studies generally with "low" to "probably low" risk of bias and rated the overall body of evidence

209 perative management was considered to have a low-risk of short-term morbidity (grade C).

210 Low-risk-of-bias studies had outcome estimates similar i

211 bphenotypes (SAMS) to classify patients into low-risk or high-risk groups based on the 52-gene signat

212 e 2 superiority trial of adult patients with low-risk or International Prognostic Scoring System inte

213 Eighty-eight healthy, HIV-uninfected, low-risk participants were enrolled in 6 United States c

214 increase in CKD events compared to those at low risk; participants at high CKD risk had a 1.31-fold

215 f reporting showed that male sex (P = .009), low-risk patient (P < .0001), self injury (P = .010), tr

216 ore (FRS); drains were omitted in negligible/low risk patients and drain fluid amylase (DFA) was meas

217 POPFs developed in the 70 (26.9%) negligible/low risk patients.

218 HCC patients into prognostic subgroups, with low-risk patients (<10 points) demonstrating excellent m

219 Low-risk patients (0 to 1 risk indicators; n = 8,032; 45

220 rs of studies provided data on the number of low-risk patients (no new ischemia on ECG and hs-cTnT me

221 eter aortic valve replacement eligibility in low-risk patients across 37 advanced economies.

222 re urgently needed to avoid overtreatment of low-risk patients and to prioritize alternative approach

223 s was used to discriminate between high- and low-risk patients and to select the most important progn

224 No low-risk patients died.

225 ients, and 378 890 (95% CI, 205 130-610 210) low-risk patients eligible for transcatheter aortic valv

226 Fourteen (0.5%) low-risk patients had AMI.

227 Low-risk patients had an m-HS</=3 and had either hs-cTnT

228 None of the 2,823 low-risk patients required neurosurgical intervention (n

229 blood cell count, >10 x 10(9)/L), as well as low-risk patients who experienced leukocytosis during in

230 withhold empirical antifungal therapy in IFD low-risk patients with prolonged FN.

231 96% (52 of 54 in high-risk and 127 of 133 in low-risk patients).

232 Among low-risk patients, 60 patients (45%) required either GO

233 In low-risk patients, incidence of MACEs was 2.0% (95% CI,

234 nsport profiles through mucus from high- and low-risk patients.

235 etically high-risk patients and only 2.3 for low-risk patients.

236 monotherapy may be considered in very select low-risk patients.

237 treatment significantly stratified high- and low-risk patients.

238 ts but not significantly so in nutritionally low-risk patients.

239 In the 43 studies of HCV mono-infected "low-risk" patients (n = 7969) the pooled recurrence rate

240 change with variations in the proportion of "low-risk" patients seen in other centers.

241 itigate overtreatment in young patients with low-risk PCa in the early term.

242 ysis or embolectomy is reasonable, while for low-risk PE, anticoagulation alone is often chosen.

243 ociated with subsequent renal dysfunction in low-risk pediatric patients, especially in those older t

244 Practices categorized as low risk performed the best on the composite quality sco

245 ary endpoint, small-duct PSC characterized a low-risk phenotype in both sexes (adjusted HR for men, 0

246 1732 (19%) positron emission tomographies at low-risk physiological severity CFR >/=2.3 to CFR <2.0,

247 ong with application of an m-HS identified a low-risk population that might be able to be directly di

248 avourable in CKD and KT as compared with the low-risk population.

249 minimize nonreproducible positive results in low-risk populations.

250 ot significantly different between high- and low-risk pregnant women.

251 rriers (1%) underwent surgical resection for low-risk PRL.

252 6% and 59%, respectively, were assigned to a low-risk profile by the 70-GS (kappa, 0.02; 95% CI, -0.0

253 , and generic pharmacological compounds with low-risk profiles that are already in routine clinical u

254 mong patients who had 2 (n=355) or 3 (n=193) low-risk prognostic features at follow-up, including a c

255 lance has become the dominant management for low-risk prostate cancer among men in Sweden, with the h

256 % (380 of 665) to 91% (939 of 1027) for very-low-risk prostate cancer and from 40% (1159 of 2895) to

257 rd of care, active surveillance, in men with low-risk prostate cancer in a phase 3 trial.

258 Recommendations For patients with low-risk prostate cancer who require or choose active tr

259 apy, a novel tissue-preserving treatment for low-risk prostate cancer, has shown favourable safety an

260 40% (1159 of 2895) to 74% (1951 of 2644) for low-risk prostate cancer, with the strongest increase oc

261 e (AS) is increasingly accepted for managing low-risk prostate cancer, yet there is no consensus abou

262 ernative to immediate treatment for men with low-risk prostate cancer.

263 seen in the use of observation for men with low-risk prostate cancer.

264 ted in the first trimester of pregnancy from low-risk, public maternity clinics in metropolitan Melbo

265 Survival of low-risk recipients who received EG was significantly be

266 10 (5.9%) patients with high, moderate, and low risk, respectively.

267 6] years), with 10.8% eligible for immediate low-risk reverse triage and 13.2% for discharge by 96 ho

268 of most SAEs was manageable, demonstrating a low-risk safety profile for IS collection even among sev

269 d Facebook may be an overlooked high-return, low-risk science outreach tool in which scientists can p

270 RHF risk ranged from 11% (low risk score 0-2) to 43.1% (high risk score >4; P<0.00

271 tional longitudinal study of fetal growth in low-risk singleton pregnancies of women of high or middl

272 perficial or nodular basal cell carcinoma at low-risk sites in our noninferiority randomized controll

273 le negative breast cancer models, but not in low-risk slow-growing tumours.

274 gnificantly decreased, and the percentage of low-risk SPECT tests increased despite decreased SPECT u

275 particularly prognostic among patients with low-risk SSIGN tumors (HR, 6.1; 95% CI, 3.4 to 11.1; P <

276 sent in 2,815 of the 2,823 patients assigned low-risk status (NPV, 99.7% [95% CI: 99.4%-99.9%]).

277 The instrument assigned low-risk status to 2,815 of 11,003 patients who did not

278 The instrument assigned low-risk status to 2,823 of 11,350 patients who did not

279 tively low dose of celecoxib administered to low-risk subjects is associated with approximately the s

280 ovides robust discrimination of high- versus low-risk subjects.

281 shown to effectively identify a substantial low-risk subset of patients possibly safe for early disc

282 cluding 4693, 15403, and 17115 men with very-low-risk (subset of the low-risk group) (clinical stage,

283 ost 80% of all tests performed in 2012 had a low-risk summed stress score compared with 29% in 1991 (

284 idence was only 1% for siblings ( P < .001 v low-risk survivors).

285 Intraoperative (18)F-FDG CLI is a promising, low-risk technique for intraoperative assessment of tumo

286 High-risk SPECT tests declined, whereas low-risk tests increased markedly.

287 er (BP), at high familial risk of BP, and at low risk to identify endophenotypes for BP.

288 s novel antibacterial mode of action holds a low risk to induce bacterial resistance, and provides va

289 A low-risk tool was developed and internally validated fro

290 Among the cohort, 59.1% had low-risk tumor characteristics (PSA < 10 ng/mL and Gleas

291 ofetal proteins and stem-cell markers, while low-risk tumors had low lin-28 homolog B and lethal-7 ex

292 l sequences occurred more frequently in very low-risk tumors.

293 for each method separated the same groups of low-risk (volume </= cutoff) from high-risk patients (vo

294 for Research and Treatment of Cancer status (low risk vs high risk), line of therapy (second line vs

295 ity facilitated stable energetic rewards and low risk, while weak fidelity facilitated high rewards a

296 observation alone after nephrectomy in very low-risk Wilms tumor (defined as stage I favorable histo

297 e AREN0532 study enrolled patients with very low-risk Wilms tumor confirmed by central review of path

298 pansion of an observation alone strategy for low-risk Wilms tumor incorporating both clinical feature

299 f an older sibling with ASD, and 122 were at low risk with no family history of ASD.

300 ailability of CAC data in a sizable group of low-risk women from the general population together with